Effector Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.63
- Today's High:
- $0.67
- Open Price:
- $0.65
- 52W Low:
- $0.338
- 52W High:
- $1.76
- Prev. Close:
- $0.633
- Volume:
- 151808
Company Statistics
- Market Cap.:
- $47.57 million
- Book Value:
- -0.114
- Revenue TTM:
- $3.55 million
- Operating Margin TTM:
- -996.09%
- Gross Profit TTM:
- $-19760000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -61.94%
- Return on Equity TTM:
- -350.11%
Company Profile
Effector Therapeutics Inc had its IPO on 2021-08-26 under the ticker symbol EFTR.
The company operates in the Healthcare sector and Biotechnology industry. Effector Therapeutics Inc has a staff strength of 15 employees.
Stock update
Shares of Effector Therapeutics Inc opened at $0.65 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.63 - $0.67, and closed at $0.64.
This is a +0.47% increase from the previous day's closing price.
A total volume of 151,808 shares were traded at the close of the day’s session.
In the last one week, shares of Effector Therapeutics Inc have slipped by -13.35%.
Effector Therapeutics Inc's Key Ratios
Effector Therapeutics Inc has a market cap of $47.57 million, indicating a price to book ratio of 1.5445 and a price to sales ratio of 5.2547.
In the last 12-months Effector Therapeutics Inc’s revenue was $3.55 million with a gross profit of $-19760000 and an EBITDA of $-35315000. The EBITDA ratio measures Effector Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Effector Therapeutics Inc’s operating margin was -996.09% while its return on assets stood at -61.94% with a return of equity of -350.11%.
In Q1, Effector Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 117%.
Effector Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.09 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Effector Therapeutics Inc’s profitability.
Effector Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.6626. Its price to sales ratio in the trailing 12-months stood at 5.2547.
Effector Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $21.93 million
- Total Liabilities
- $26.65 million
- Operating Cash Flow
- $9.03 million
- Capital Expenditure
- $13000
- Dividend Payout Ratio
- 0%
Effector Therapeutics Inc ended 2024 with $21.93 million in total assets and $0 in total liabilities. Its intangible assets were valued at $21.93 million while shareholder equity stood at $-4813000.00.
Effector Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $26.65 million in other current liabilities, 4000.00 in common stock, $-153580000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $10.31 million and cash and short-term investments were $19.01 million. The company’s total short-term debt was $20,303,000 while long-term debt stood at $0.
Effector Therapeutics Inc’s total current assets stands at $20.89 million while long-term investments were $0 and short-term investments were $8.70 million. Its net receivables were $0 compared to accounts payable of $3.79 million and inventory worth $0.
In 2024, Effector Therapeutics Inc's operating cash flow was $9.03 million while its capital expenditure stood at $13000.
Comparatively, Effector Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.64
- 52-Week High
- $1.76
- 52-Week Low
- $0.338
- Analyst Target Price
- $7.38
Effector Therapeutics Inc stock is currently trading at $0.64 per share. It touched a 52-week high of $1.76 and a 52-week low of $1.76. Analysts tracking the stock have a 12-month average target price of $7.38.
Its 50-day moving average was $0.73 and 200-day moving average was $0.6 The short ratio stood at 0.36 indicating a short percent outstanding of 0%.
Around 790.4% of the company’s stock are held by insiders while 6403.3% are held by institutions.
Frequently Asked Questions About Effector Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors and in combination with fulvestrant and abemaciclib in a Phase 2a open-label expansion cohort to treat patients with ER+ breast cancer. eFFECTOR Therapeutics, Inc. has a research collaboration and license agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.